A01 Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) for the treatment of bladder cancer. Brittany Bunch, Moffitt Cancer Center, Tampa, FL, USA.

A02 Photodynamic therapy in combination with immunotherapy enhances the long-term cure of bladder cancer in tumored mice. Farukh Durrani, Roswell Park Cancer Institute, Buffalo, NY, USA.

A03, PR04 Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes. Markus Eckstein, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

A04 DNA damage repair gene mutations and associated tumor immune landscape as biomarkers of response to immunotherapy in muscle invasive urothelial cancer. Madhuri Koti, Queen’s University, Kingston, ON, Canada.

A05 Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from advanced bladder cancer for adoptive immunotherapy. Qiang Li, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A06, PR03 Can immunological biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC? Melinda Lillesand, Stavanger University Hospital, Stavanger, Rogaland, Norway.

A07 A marker to optimise BCG dosing schedules for immunotherapy. Ratha Mahendran, National University of Singapore, Singapore, Singapore.

A08 Application of Miltuximab®-IRDye800 for near-infrared fluorescence imaging of urothelial carcinoma in vivo. Dmitry Polikarpov, Macquarie University, Sydney, NSW, Australia.

A09 Photoimmunotherapy (PIT) for treatment of bladder cancer. Reema Railkar, National Cancer Institute, Bethesda, MD, USA.

A10 Logical modelling of tumor-immune cross-talk network to predict the mechanism of immune evasion in muscle invasive bladder cancer (MIBC). Shruti Shah, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A11 Generation and characterization of immune competent syngeneic model of muscle invasive bladder cancer (MIBC). Shruti Shah, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A12 Bladder cancer derived extracellular vesicles and immune activation. Sin Mun Tham, National University of Singapore, Singapore, Singapore.
A13 Entinostat enhances antitumor immune responses and cooperates with PD-1 blockade in bladder cancer mouse models. Andrew Truong, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

A14 Next-generation sequencing of Bacille Calmette-Guerin (BCG) unresponsive tumors identifies actionable alterations for potential targeted therapy in non-muscle invasive bladder cancer. Aleksandra Walasek, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A15 Uninflamed immunological microenvironment of muscle invasive bladder cancer associates with activating FGFR3 gene alterations. Veronika Weyrerer, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

A16 Characterization of ErbB family expression in intratibial bladder cancer xenografts: Considerations for preclinical modeling. Luke Broes, University of Michigan, Ann Arbor, MI, USA.

A17 Gene expression changes associated with metastasis in mice with bladder cancer. Kesavan Esuvaranathan, National University Health System, Singapore, Singapore.

A18 Targeting epigenetic dysregulation in bladder cancer through inhibition of EZH2. Patricia Keller, Constellation Pharmaceuticals, Inc., Cambridge, MA, USA.

A19 A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC). Timothy Owens, Principia Biopharma, South San Francisco, CA, USA.

A20 Disruption and restoration of pioneer transcription factor function in bladder cancer. Caroline Schuerger, Cleveland Clinic, Cleveland, OH, USA.

A21 TRIM29 promotes invasion and migration of bladder cancer cells by regulating myosin-intermediate filament network and focal adhesion. Yin Wang, University of Michigan, Ann Arbor, MI, USA.

A22 STAG2, a novel genetic regulator of bladder cancer. Anna Woloszynska, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
A23 The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial cancer. Christopher Hoimes, Case Western Reserve University/University Hospitals Seidman Center, Cleveland, OH, USA.


A25 Effect of pre-existing conditions on bladder cancer diagnosis: A cohort study using electronic primary care records. Madeline Carney, USF Morsani College of Medicine, Tampa, FL, USA.

A26, PR05 Similarities in molecular subtypes and subtype immune patterns between naturally-occurring canine and human invasive bladder cancer. Deborah Knapp, Purdue University, West Lafayette, IN, USA.

A27 Fidelity of a PDX-CR model for bladder cancer. Abdul Mondal, Georgetown University Medical Center, Washington, D.C., USA.

A28 Deregulation of KMT2D promotes squamous differentiation in a mouse model of muscle-invasive bladder cancer. Lijie Rong, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.

A29 Multiplex functional genomics assay to deconvolute compound genetic drivers of bladder cancer. Alicia Wong, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.